UPDATE: JPMorgan Downgrades Elevation Oncology (ELEV) to Underweight
Tweet Send to a Friend
(Updated - November 10, 2022 5:29 AM EST)
JPMorgan analyst Anupam Rama downgraded Elevation Oncology (NASDAQ: ELEV) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Anupam Rama downgraded Elevation Oncology (NASDAQ: ELEV) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
